icon3

China Biopharmaceuticals Market By Therapeutic Area (Anti-infective, Cancer, Others.) and Forecast - 2026

  • OI-75
  • |
  • Published date: Mar, 2019
  • |
  • Biopharmaceuticals
  • |
  • Pages

Biopharmaceuticals, or biologics, are one of the world's fastest-growing class of medicines: among the top 10 therapeutics available on the market today, eight are biopharmaceuticals. Unlike synthetic drugs, they are called as the products of live organisms and are better targeted to everything from cancer and diabetes to immune disorders, like arthritis. Biopharmaceuticals are going to offer several benefits, including highly effective and potent action, fewer side effects, and the potential to cure diseases actually rather than treat the symptoms merely, which have significantly increased the biopharmaceutical products demand in the market. China is known to be a relative newcomer to the biopharmaceutical industry. Biological therapeutics have been on the market only since the 1990s by multinational corporations in China, but the country has been making significant and rapid progress ever since.


Market Overview


China is known to be the world's second largest pharmaceutical market after the US and is expected to overtake the US by 2020. The biopharmaceutical industry is china’s thriving sector, is forecasted to grow to about 15% of GDP in 2030, and thus becoming an important economic growth point. China is moving from firstly a generic market to a global biopharmaceutical market. The Chinese biopharmaceutical industry is developing to establish itself as a research-driven, domestic, and market-oriented industry. On the other hand, China is also emerging as a global outsourcing center for many overseas biopharmaceutical companies, especially those in the United States and Europe. The Chinese biopharmaceutical industry is actively investing in both the biologics pipeline for innovative domestic products and the bio-manufacturing infrastructure needed to commercialize these innovations. 


Anyway, as companies are continuing to grow their business in China, several issues have to be resolved, such as biogenerics versus innovative discoveries, quality and regulatory oversight, intellectual property protection, access to venture capital, and enterprise management. The other opportunity is that there are an increasing number of new drugs that are being developed by Chinese companies where the clinical trials and marketing in the US or Europe will be better handled by a Western biopharma company with regional regulatory expertise, in-place sales, and marketing resources, and, if needed, funding.


Key Developments



  • In December 2018, the State Drug Administration (NMPA) has announced the approval of the list of the first domestically produced PD-1 monoclonal antibody, i.e., tripril monoclonal antibody injection that was developed by Suzhou Zhonghe Biomedical Co., Ltd. (A subsidiary of Shanghai Junshi Biosciences Co., Ltd.) used to treat local progression or metastatic melanoma after the failure of previous standard treatment.

  • AMOYTOP BIOTECH, the leading manufacturer of recombinant biopharmaceutical products in China with cGMP, produces Molgramostim, Filgrastim, Oprelvekin, Interferon-alfa-2a, Interferon-alfa-2b, Interferon gamma, Interferon-2, and Somatropin, and provides bio-reagents, such as Interleukin-4, TNF, and recombinant human SOD.


Segmentation


The biopharmaceutical market in china is presented as follows:


By Company: Examples of companies in the Chinese biopharmaceutical market include Amoytop Biotech, Beijing Continent Pharmaceuticals, Fusogen, Shanghai Huaguan Biochip, Sibiono Genetech, Abbott, Roche, Pfizer, Gsk,Novartis.


By Therapeutic Area: Examples of Chinese biopharmaceutical market treating areas are Anti-infective, Cancer, Diabetes, Dementia, Depression.


Biopharmaceuticals have shown a reduction in the number of deaths because of cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market. However, on the road to innovation, still, China has a lot of things to do, such as speeding up pharmaceutical policy reform, development of cross-border technology intermediary, R & D internationalization, accelerating the realization of the healthy China 2030 strategic.

Report Description: The report covers in-depth analysis on Biopharmaceuticals Market in China. The report assesses the pipeline Biopharmaceuticals by stage of development (early development, pre-clinical, clinical and in approval), by application (Anti-infective, Cancer, Diabetes, Dementia, Depression and other diseases). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.


The report includes in-depth company profiles of key players in Biopharmaceuticals Market in China. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.


The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.


Scope:



  • Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Biopharmaceuticals Market in China.

  • Provides a comparative analysis of key marketed products and pipeline

  • Provides key information on players involved on Biopharmaceuticals Market in China

  • Provides a complete overview of market segments and the regional outlook of Biopharmaceuticals Market in China

  • Provides in-depth coverage of key news related toBiopharmaceuticals Market in China, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:




  • Data Collation (Primary & Secondary)




  • In-house Estimation (Based on proprietary databases and Models)




  • Market Triangulation




  • Forecasting




  • Market-related information is assembled from both primary and secondary sources. 






  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 






  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others. 






  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. 





 


REPORT YOU MIGHT BE INTERESTED

Choose Licence Type

$3,850.00
$4,950.00


(For Coporate Licence Only) Complementary
Credit card Logo
Inquiry Before Buying

Related Reports


Contact Us

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)